p r o d u c t s
According to the National Library of Medicine’s online service, hundreds of articles, which have all been reviewed from scientific journals by industry peers have indicated there are many conditions in which CBD may have therapeutic value. Additionally, added to these
very technical reports, O’Shaughnessy’s Online articles as well as other articles from CBD and general interest scientific research, have stated the same. Even though CBD compounds have a pharmacological receptor response in all mammals, The data from these experiments and preclinical research performed on animals will not necessarily be relevant to humans.
GW Pharmaceuticals has successfully completed trials of Sativex (GW is developing a portfolio of cannabinoid medicines, including Sativex for the treatment of MS spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy) A CBD rich extract from a cannabis plant, focusing on those neuropathic pain sufferers. Additionally, studies of synthetic vs whole plant CBD have been Israel and Brazil.
Unfortunately, political constraints have blocked clinical-oriented CBD research in the United States. Articles occasionally study the potentially therapeutic effects of other CBD found in plants such as the raw acid form of cannabidiol named CBDA. Also included are articles on THC, THCV and CBDV (Cannabidivarin, suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression). There are also some studies on the endocannabinoid system without a focus on CBD
Included are a few studies which spotlight different facets of the endocannabinoid system. These studies do not have an emphasis on CBD.
By Selecting a medical condition listed below you can view the science. Conditions In the footer of each page, you will also find conditions.
Copyright Bioprocessing LLC. All rights reserved.